Skip to main content

Xofigo FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 27, 2021.

FDA Approved: Yes (First approved May 15, 2013)
Brand name: Xofigo
Generic name: radium Ra 223 dichloride
Dosage form: Injection
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Prostate Cancer

Xofigo (radium 223 dichloride) is an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer.

Development timeline for Xofigo

May 15, 2013Approval FDA Approves Xofigo for Advanced Prostate Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.